Leukemia, Acute Clinical Trials

2 recruiting

Leukemia, Acute Trials at a Glance

21 actively recruiting trials for leukemia, acute are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Guangzhou, Guiyang, and Chengdu. Lead sponsors running leukemia, acute studies include Institute of Hematology & Blood Diseases Hospital, China, Mats Heyman, and National Cancer Institute (NCI).

Browse leukemia, acute trials by phase

Treatments under study

About Leukemia, Acute Clinical Trials

Looking for clinical trials for Leukemia, Acute? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leukemia, Acute trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leukemia, Acute clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Not Applicable

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

CancerOncologyMyeloid Leukemia, Acute
University of Rochester1,020 enrolled4 locationsNCT06697600
Recruiting
Phase 3

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Leukemia, Acute Lymphoblastic
Mats Heyman6,430 enrolled139 locationsNCT04307576
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 1

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Chronic Myeloid LeukemiaMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics130 enrolled7 locationsNCT05362773
Recruiting
Phase 3

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, China150 enrolled24 locationsNCT07152041
Recruiting

A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Leukemia, Acute Lymphoblastic
Mats Heyman500 enrolled53 locationsNCT03911128
Recruiting
Phase 2Phase 3

Newly-diagnosed Pediatric T-cell ALL Protocol

Acute Lymphoblastic LeukemiaChildhood Leukemia, Acute LymphoblasticT Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China610 enrolled27 locationsNCT06855810
Recruiting
Phase 2Phase 3

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Childhood Leukemia, Acute LymphoblasticAcute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China3,000 enrolled27 locationsNCT06882057
Recruiting

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

MDSLeukemia, Acute
Abramson Cancer Center at Penn Medicine20 enrolled1 locationNCT03680677
Recruiting
Phase 2Phase 3

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Childhood Leukemia, Acute LymphoblasticAcute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China1,800 enrolled26 locationsNCT06764238
Recruiting

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments

Myeloid Leukemia, Acute
IRCCS Azienda Ospedaliero-Universitaria di Bologna20 enrolled1 locationNCT06764459
Recruiting
Phase 1Phase 2

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

Lymphoma, Non-HodgkinLeukemia, Acute Lymphoblastic
University of Sao Paulo81 enrolled5 locationsNCT06101381
Recruiting
Not Applicable

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Leukemia, Acute LymphoblasticMyeloid Leukemia, Acute
Azienda Ospedaliero-Universitaria di Parma100 enrolled8 locationsNCT06626893
Recruiting
Phase 2

BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.

Lymphoblastic Lymphoma, AdultLymphoblastic Leukemia, Acute T-cell
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine206 enrolled1 locationNCT06598722
Recruiting

Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology

LymphomaLeukemiaLeukemia, Chronic+2 more
European Institute of Oncology50 enrolled1 locationNCT06335277
Recruiting
Phase 1

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Myelodysplastic SyndromesLeukemia, Acute Lymphocytic (ALL)Leukemia, Acute Myelogenous (AML)
Zhujiang Hospital30 enrolled1 locationNCT03291444
Recruiting
Phase 2

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

CARB-cell Acute Lymphoblastic LeukemiaLymphoblastic Leukemia in Children+3 more
KK Women's and Children's Hospital40 enrolled2 locationsNCT05648019
Recruiting
Phase 1

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

CARRefractory LeukemiaLymphoblastic Leukemia in Children+4 more
National University Hospital, Singapore20 enrolled1 locationNCT05043571
Recruiting
Phase 1

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

CARLymphoblastic Leukemia in ChildrenLymphoblastic Leukemia+3 more
National University Hospital, Singapore40 enrolled1 locationNCT05038696